| Name | Title | Contact Details |
|---|---|---|
Joey Tamboli |
Director of Information Security | Profile |
Boehringer Wound Systems is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
eSight empowers the low vision community and advocates to #SeeNewPossibilities for people with macular degeneration, diabetic retinopathy, and 50+ other conditions that cause vision loss. Founded by electrical engineer, Conrad Lewis, who wanted to help his two legally blind sisters see, eSight has since grown to become the leading sight enhancement platform led by an executive team with the vision to do more. After seven years of research and development, the first eSight Eyewear prototype was released in 2013. Since then, the vision-enhancing electronic technology has changed the lives of thousands of people living with visual impairments and legal blindness by allowing them to retain their independence and achieve greater visual acuity at home, school, work, and play. Soon after the release of eSight 3, Time Magazine named eSight in its list of “The 25 Best Inventions in 2017” and Buzzfeed featured the device on its roster of “6 Inventions Changing British People`s Lives In 2017”. Following eSight 3, the team continued to develop its technology and, in 2020, launched its latest model — eSight 4. It was thoughtfully crafted to be wireless and hands-free allowing users to retain their mobility as well as be lightweight and streamlined for all-day comfort. The eSight 4 was later recognized as the “Best Wearable/Healthcare Hardware/Software of 2021” by the Tech Ascension Awards, which honors companies that possess the most innovative technology in their respective industry.
International Technology Industry is a Burke, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Philips Respironics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.